APEX1 and Duchenne muscular dystrophy: As chronic inflammation and oxidative stress are hallmarks of DMD pathology, we hypothesized that APE1/Ref‐1 protein would be upregulated in dystrophic muscles and that APE1/Ref‐1 inhibition with APX3330 treatment would ameliorate dystrophic hindlimb muscle pathology and improve contractile function in C57Bl/10 mdx mice.